Company Profile
Salarius Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- SLRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for SLRX.
Company overview
Business overview
Salarius Pharmaceuticals is a biotechnology company focused on oncology and epigenetic or related cancer biology. Its story is built around seeking targeted cancer therapies for difficult tumors.
Geographic Base and Sector Classification
Salarius is headquartered in the United States and listed on NASDAQ. It sits in small-cap oncology biotechnology.
Business Model Characteristics
The company depends on clinical data, partnership options, and capital discipline. Investors usually track early readouts and whether the pipeline can maintain enough momentum to matter.
Position Within the Biotechnology Landscape
Salarius occupies a catalyst-sensitive oncology niche within biotech. The stock is driven by proof-of-concept and the market's confidence in the company's cancer thesis.
Future catalysts
Salarius is a legacy / closeout story now, so the catalysts are any remaining strategic or asset-resolution update rather than a live oncology milestone. The market is mainly focused on residual value.
Recent news
- 01
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
Source: Salarius Pharmaceuticals
- 02
- 03
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026
Source: Salarius Pharmaceuticals
- 04
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Source: Salarius Pharmaceuticals
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Salarius Pharmaceuticals do?
Salarius Pharmaceuticals is a biotechnology company focused on oncology and epigenetic or related cancer biology. Its story is built around seeking targeted cancer therapies for difficult tumors.
On which exchange is SLRX stock listed?
Salarius Pharmaceuticals (SLRX) is associated with NASDAQ, United States, Biopharma.
What is Salarius?
Salarius is a legacy / closeout story now, so the catalysts are any remaining strategic or asset-resolution update rather than a live oncology milestone.
Which conditions is Salarius Pharmaceuticals targeting with Salarius?
Salarius Pharmaceuticals is associated with oncology, cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.
How does Salarius Pharmaceuticals describe recent progress with Salarius?
Salarius is a legacy / closeout story now, so the catalysts are any remaining strategic or asset-resolution update rather than a live oncology milestone.
What is Pharmaceuticals?
Salarius Pharmaceuticals is a biotechnology company focused on oncology and epigenetic or related cancer biology.
What should investors watch for with Pharmaceuticals?
Salarius is a legacy / closeout story now, so the catalysts are any remaining strategic or asset-resolution update rather than a live oncology milestone. The market is mainly focused on residual value.
What future catalysts are investors watching for Salarius Pharmaceuticals?
Salarius is a legacy / closeout story now, so the catalysts are any remaining strategic or asset-resolution update rather than a live oncology milestone. The market is mainly focused on residual value.